Charles de Wet, Boehringer Ingelheim’s medical director for the UK and Ireland, says the company is wholeheartedly committed to data transparency but does not favour the approach being adopted by the AllTrials campaign.
News
GSK targets bioelectronic meds with $50 million fund
GlaxoSmithKline has launched a $50 million venture capital fund that will invest in companies that pioneer medicines using electrical impulses to regulate the body’s organs and functions.
Icon-NCTRC partnership to facilitate CTs in Taiwan
Icon, the global provider of outsourced development services based in Ireland, has formed a partnership with the National Clinical Trials and Research Centre (NCTRC) at the National Taiwan University Hospital to improve the set-up and management of clinical studies in Taiwan.
Lilly backs Ixchelsis, a start-up born at Pfizer
Ixchelsis, a start-up company that has come out of Pfizer’s former R&D site at Sandwich, UK, is progressing a treatment for premature ejaculation boosted by the backing of Eli Lilly.
Novo Nordisk profits leap thanks to Victoza
Novo Nordisk has posted yet another strong set of figures, helped by strong sales of its diabetes drug Victoza.
Amgen to raise bid for Onyx, claims report
Amgen is rumoured to be planning a higher offer to acquire Onyx Pharmaceuticals, having had an earlier bid of $120 per share rejected by the cancer specialist.
Antidepressant Brintellix tipped as blockbuster
Among the new agents entering the unipolar depression market over the next decade, Lundbeck/Takeda Pharmaceutical’s Brintellix is set to achieve blockbuster status by 2022, according to new forecasts.
NHS must build culture of learning – Berwick review
NHS staff should be supported to learn from mistakes, and patients and carers must be put above all to make the NHS a world leader in patient safety, says a former adviser to US President Barack Obama.
Novartis’ Afinitor fails in liver cancer study
Novartis has suffered a setback on getting expanded approvals for Afinitor after the drug failed in a late-stage trial as a treatment for advanced liver cancer.
Novartis signs inflammation pact with Ensemble
Novartis has linked up with Ensemble Therapeutics to develop the latter’s in-house experimental drug candidates that block the inflammatory protein interleukin-17, a target for a number of autoimmune diseases.
Pay-for-delay fine widens Lundbeck loss
Losses at Lundbeck have widened for the second quarter, hit by the effects of a ‘pay-for-delay’ fine from the European Commission, although its new products are performing well.
Price cuts good, more competition better – Oxfam, MSF
After Roche linked up with the Medicines Patent Pool on its cytomegalovirus drug Valcyte, two leading charities have welcomed the move but called for even broader access to medicines for poorer countries.
TransCelerate’s Comparator Network now active
TransCelerate BioPharma, the non-profit organisation set up by leading pharmaceutical companies last September to advance innovation and tackle inefficiencies in R&D, has put into operation a Comparator Network to ensure rapid, reliable sourcing of quality medicines for clinical trials.
Roche’s Perjeta not value for money, says NICE draft
The NHS is to be advised that it should not routinely provide Roche’s Perjeta (pertuzumab) as a treatment for a type of advanced breast cancer, because it does not represent value for money, says new draft guidance from the National Institute for Health and Care Excellence.
Thumbs-down for Otsuka’s tolvaptan for kidney disorder
Otsuka Pharmaceutical Co has suffered a setback after advisors to the US Food and Drug Administration decided not to recommend the Japanese drugmaker’s already-approved tolvaptan for a kidney disorder.
